UA107657C2 - Похідні бензофурану - Google Patents

Похідні бензофурану

Info

Publication number
UA107657C2
UA107657C2 UAA201110792A UAA201110792A UA107657C2 UA 107657 C2 UA107657 C2 UA 107657C2 UA A201110792 A UAA201110792 A UA A201110792A UA A201110792 A UAA201110792 A UA A201110792A UA 107657 C2 UA107657 C2 UA 107657C2
Authority
UA
Ukraine
Prior art keywords
optionally substituted
ring
represent
hydrogen atom
lower alkyl
Prior art date
Application number
UAA201110792A
Other languages
English (en)
Russian (ru)
Inventor
Тецуя Цукамото
Такеші Вакабаяші
Таічі Охра
Original Assignee
Такеда Фармасьютікал Компані Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютікал Компані Лімітед filed Critical Такеда Фармасьютікал Компані Лімітед
Publication of UA107657C2 publication Critical patent/UA107657C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Представлений винахід стосується сполуки, представленої наступною формулою (І): EMBED ISISServer , (I) в якій: кільце А означає необов'язково заміщене піперазинове кільце, необов'язково заміщене морфолінове кільце, або необов'язково заміщене гомопіперазинове кільце; R1 і R2 є однаковими або відмінними один від одного, і являють собою атом водню або необов'язково заміщений нижчий алкіл; R3 і R4 є однаковими або відмінними один від одного, і являють собою атом водню або галогенований або негалогенований нижчий алкіл; R5-R7 є однаковими або відмінними один від одного, і являють собою атом водню, гідрокси, необов'язково заміщений нижчий алкіл, необов'язково заміщений нижчий алкеніл, необов'язково заміщений нижчий алкокси, необов'язково заміщений циклоалкіл, необов'язково заміщений арил, необов'язково заміщене ароматичне гетероциклічне кільце, необов'язково заміщений аміно, або ацил; і EMBED ISISServer означає простий зв'язок або подвійний зв'язок, або її солі.
UAA201110792A 2009-03-10 2010-03-09 Похідні бензофурану UA107657C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009056719 2009-03-10
PCT/JP2010/054286 WO2010104194A1 (en) 2009-03-10 2010-03-09 Benzofuran derivatives

Publications (1)

Publication Number Publication Date
UA107657C2 true UA107657C2 (uk) 2015-02-10

Family

ID=42224778

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201110792A UA107657C2 (uk) 2009-03-10 2010-03-09 Похідні бензофурану

Country Status (37)

Country Link
US (4) US8288390B2 (uk)
EP (2) EP2781513A1 (uk)
JP (2) JP5746631B2 (uk)
KR (1) KR20110128913A (uk)
CN (2) CN103965147B (uk)
AR (1) AR076098A1 (uk)
AU (1) AU2010221979A1 (uk)
BR (1) BRPI1009252A2 (uk)
CA (1) CA2754904A1 (uk)
CL (1) CL2011002206A1 (uk)
CO (1) CO6420340A2 (uk)
CR (1) CR20110474A (uk)
CY (1) CY1115469T1 (uk)
DK (1) DK2406243T3 (uk)
DO (1) DOP2011000281A (uk)
EA (1) EA201171020A1 (uk)
EC (1) ECSP11011318A (uk)
ES (1) ES2487616T3 (uk)
HK (1) HK1202293A1 (uk)
HR (1) HRP20140687T1 (uk)
IL (1) IL214667A0 (uk)
MA (1) MA33159B1 (uk)
MX (1) MX2011009394A (uk)
NZ (1) NZ594847A (uk)
PE (1) PE20120357A1 (uk)
PL (1) PL2406243T3 (uk)
PT (1) PT2406243E (uk)
RS (1) RS53416B (uk)
SG (1) SG173757A1 (uk)
SI (1) SI2406243T1 (uk)
SM (1) SMT201500027B (uk)
TN (1) TN2011000422A1 (uk)
TW (1) TWI477497B (uk)
UA (1) UA107657C2 (uk)
UY (1) UY32481A (uk)
WO (1) WO2010104194A1 (uk)
ZA (1) ZA201106045B (uk)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010104194A1 (en) * 2009-03-10 2010-09-16 Takeda Pharmaceutical Company Limited Benzofuran derivatives
US20130005710A1 (en) 2009-11-18 2013-01-03 Tetsuya Tsukamoto Aminopyridine derivative
MX2014009923A (es) 2012-02-20 2015-08-10 Basf Se Intensificación de la acción antimicrobiana de biocidas con polimeros.
US9908680B2 (en) 2012-09-28 2018-03-06 Kimberly-Clark Worldwide, Inc. Tree-free fiber compositions and uses in containerboard packaging
US9816233B2 (en) * 2012-09-28 2017-11-14 Kimberly-Clark Worldwide, Inc. Hybrid fiber compositions and uses in containerboard packaging
KR101676212B1 (ko) * 2012-10-01 2016-11-14 에프. 호프만-라 로슈 아게 Cns 활성제로서 벤즈이미다졸
KR101716099B1 (ko) * 2013-09-12 2017-03-13 에프. 호프만-라 로슈 아게 인돌-카복스아마이드 유도체
SG11201912770SA (en) 2017-06-23 2020-01-30 Kyowa Kirin Co Ltd a, ß-UNSATURATED AMIDE COMPOUND
CN109580790A (zh) * 2017-09-28 2019-04-05 安徽省庆云医药股份有限公司 一种液相色谱法分离测定西洛多辛及其光学异构体的方法
CN108530405A (zh) * 2018-05-08 2018-09-14 南京晓庄学院 非金属路易斯酸催化烯烃分子内加成c-o键合成苯并呋喃衍生物的方法
CN109879839B (zh) * 2019-03-12 2023-04-25 沈阳大学 6-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途
CN113045523B (zh) * 2019-12-27 2022-09-23 上海泓博智源医药股份有限公司 一种咪唑啉吡啶化合物中间体的制备方法
UY39129A (es) * 2020-03-16 2021-10-29 Novartis Ag Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CN111362965B (zh) * 2020-04-27 2022-05-03 梯尔希（南京）药物研发有限公司 一种莫西菌素杂质的制备方法
CN113219085B (zh) * 2021-03-31 2022-05-13 河北国龙制药有限公司 一种2,3-二甲基溴苯有关物质的检测方法
CN113214205B (zh) * 2021-04-09 2022-06-10 南方海洋科学与工程广东省实验室(湛江) 一种色原酮衍生物的制备方法
CN115260136B (zh) * 2022-08-09 2023-08-15 嘉兴学院 一种苯酞类化合物及其制备方法
CN115724721A (zh) * 2022-12-19 2023-03-03 山东京博石油化工有限公司 一种2-取代基-4-溴苯酚的制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0106800A1 (de) 1982-10-08 1984-04-25 Ciba-Geigy Ag Furane
JPH04149546A (ja) 1990-10-15 1992-05-22 Konica Corp 有機着色物質の光褪色防止方法
TW199152B (uk) 1990-11-01 1993-02-01 Takeda Pharm Industry Co Ltd
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
DE4333254A1 (de) 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
JPH11514333A (ja) 1995-03-14 1999-12-07 プレーシス ファーマスーティカルズ インコーポレイテッド アミロイドの凝集の調節剤
DE19514567A1 (de) 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
PT929574E (pt) 1996-08-27 2005-11-30 Praecis Pharm Inc Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
JP4149546B2 (ja) 1996-12-24 2008-09-10 株式会社東芝 半導体装置の製造方法
EP0988289A2 (en) * 1997-06-05 2000-03-29 Takeda Pharmaceutical Company Limited Heterocyclic compounds, their production and use
JPH1149765A (ja) * 1997-06-05 1999-02-23 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
HU225101B1 (en) 1997-07-25 2006-06-28 Lundbeck & Co As H Indole and 2,3-dihydroindole derivatives, their preparation, use, and pharmaceutical compositions containing them
PT1136477E (pt) * 1998-12-04 2004-08-31 Takeda Chemical Industries Ltd Derivados do benzofurano processo para a sua preparacao e suas utilizacoes
DE19932314A1 (de) 1999-07-10 2001-01-11 Merck Patent Gmbh Benzofuranderivate
BR0012752A (pt) 1999-07-29 2002-04-02 Lilly Co Eli Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina
DE19958496A1 (de) 1999-12-04 2001-06-07 Merck Patent Gmbh Verfahren zur Herstellung von 5-(1-Piperazinyl)-benzofuran-2-carboxamid durch Übergangsmetallkatalysierte Aminierung
US20040094431A1 (en) * 2000-06-12 2004-05-20 Howard A. Fromson Brush graining
US20040034049A1 (en) 2000-10-05 2004-02-19 Shigenori Okawa Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells
ATE527247T1 (de) * 2001-07-05 2011-10-15 Takeda Pharmaceutical Benzokondensierte 5gliedrige heterocyclische verbindungen, verfahren zu deren herstellung und deren verwendung
KR101011657B1 (ko) * 2002-03-01 2011-01-28 다케다 야쿠힌 고교 가부시키가이샤 항우울제
ATE372342T1 (de) 2002-04-02 2007-09-15 Janssen Pharmaceutica Nv Substituierte aminoisoxazolinderivate und ihre verwendung als antidepressiva
EP1350769A1 (de) * 2002-04-04 2003-10-08 Bystronic Maschinen AG Vorrichtung und Verfahren zum Teilen von vertikalen Glasplatten
EP1553074B1 (en) 2002-08-12 2014-06-18 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
TWI355381B (en) 2003-04-23 2012-01-01 Schering Corp 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-tri
CA2525713A1 (en) 2003-05-20 2004-12-29 Genentech, Inc. Benzofuran inhibitors of factor viia
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
NZ544298A (en) 2003-06-26 2009-04-30 Takeda Pharmaceutical Cannabinoid receptor modulators including benzofuran derivatives
JP3678733B2 (ja) * 2003-10-03 2005-08-03 株式会社エヌ・ティ・ティ・ドコモ 携帯通信端末及び位置情報提供方法
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050095401A1 (en) * 2003-11-04 2005-05-05 Fuji Photo Film Co., Ltd. Image recording material and depression-and-protrusion forming method
JP2007530541A (ja) 2004-03-22 2007-11-01 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックスとしてのα−トリフルオロメチルアルコール又はアミン
TW200538118A (en) 2004-04-21 2005-12-01 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
DE102004063797A1 (de) 2004-12-30 2006-07-13 Schwarz Pharma Ag Sauerstoffhaltige annelierte Phenylpiperazin- und Phenyldiazepancarboxamide
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
PT1874781E (pt) * 2006-04-19 2009-07-27 Boehringer Ingelheim Int Di-hidro-tienopirimidinas para o tratamento de doenças inflamatórias
CA2649043C (en) 2006-04-19 2013-09-17 Astellas Pharma Inc. Azolecarboxamide derivative
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
HU230729B1 (hu) 2007-05-30 2017-12-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Új, szelektív 5HT7-receptorgátló benzofurán-származékok és eljárás előállításukra
US8382180B2 (en) * 2007-10-31 2013-02-26 Applied Material, Inc. Advanced FI blade for high temperature extraction
CA2717138A1 (en) 2008-03-05 2009-09-11 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compounds and bicyclic heteroaryl having glucagon antagonistic action useful for treating diabetes
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
WO2010104194A1 (en) * 2009-03-10 2010-09-16 Takeda Pharmaceutical Company Limited Benzofuran derivatives

Also Published As

Publication number Publication date
US8957069B2 (en) 2015-02-17
US20120046277A1 (en) 2012-02-23
ZA201106045B (en) 2012-10-31
US20100234357A1 (en) 2010-09-16
CL2011002206A1 (es) 2012-02-03
PE20120357A1 (es) 2012-05-03
HRP20140687T1 (hr) 2014-10-24
DOP2011000281A (es) 2011-10-31
JP2015044848A (ja) 2015-03-12
CN103965147B (zh) 2016-08-24
IL214667A0 (en) 2011-09-27
CR20110474A (es) 2011-12-01
TWI477497B (zh) 2015-03-21
CA2754904A1 (en) 2010-09-16
BRPI1009252A2 (pt) 2016-03-15
NZ594847A (en) 2013-10-25
ECSP11011318A (es) 2011-10-31
SG173757A1 (en) 2011-09-29
JP5841651B2 (ja) 2016-01-13
CY1115469T1 (el) 2017-01-04
PL2406243T3 (pl) 2014-10-31
US20120232096A1 (en) 2012-09-13
CN102421767A (zh) 2012-04-18
SMT201500027B (it) 2015-05-05
MA33159B1 (fr) 2012-03-01
SI2406243T1 (sl) 2014-08-29
EP2406243B1 (en) 2014-05-07
MX2011009394A (es) 2011-10-11
JP2012520238A (ja) 2012-09-06
EP2406243A1 (en) 2012-01-18
CN102421767B (zh) 2014-06-18
US20120232095A1 (en) 2012-09-13
CO6420340A2 (es) 2012-04-16
EA201171020A1 (ru) 2012-03-30
ES2487616T3 (es) 2014-08-22
US8288390B2 (en) 2012-10-16
WO2010104194A1 (en) 2010-09-16
HK1202293A1 (en) 2015-09-25
PT2406243E (pt) 2014-07-11
UY32481A (es) 2010-09-30
AR076098A1 (es) 2011-05-18
DK2406243T3 (da) 2014-07-21
TW201036960A (en) 2010-10-16
KR20110128913A (ko) 2011-11-30
TN2011000422A1 (en) 2013-03-27
RS53416B (en) 2014-12-31
EP2781513A1 (en) 2014-09-24
CN103965147A (zh) 2014-08-06
AU2010221979A1 (en) 2011-09-15
JP5746631B2 (ja) 2015-07-08

Similar Documents

Publication Publication Date Title
UA107657C2 (uk) Похідні бензофурану
MY152972A (en) Azabicyclo compound and salt thereof
MX2011008305A (es) Compuestos de piridazinona.
MX337714B (es) Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk).
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
TW200732333A (en) An oxime derivative and preparations thereof
TW200639158A (en) New compounds with therapeutic effect
TW201129556A (en) Novel antiplatelet agent
RS54638B1 (en) HCV SERIN PROTEASE INHIBITORS DERIVED FROM MACROCYCLIC PROLINE
EA201290401A1 (ru) Азотсодержащее гетероциклическое соединение и сельскохозяйственный фунгицид
TW200722432A (en) Thiazole compounds
MX2009010024A (es) Nuevo compuesto de adenina.
TNSN08372A1 (en) Heterocyclic amides for use as pharmaceuticals
MX2009012283A (es) Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
TW200745034A (en) New compounds
UA105185C2 (uk) Піроли
NO20084338L (no) Neurogenesis fremkaller eller terapeutisk neuropatimiddel omfattende alkyl eter derivater eller salter derav
MY160942A (en) Melanin production inhibitor
MX2010008637A (es) Derivado de fenilpirrol novedoso.
IN2014DN03483A (uk)
MX2015008479A (es) Compuesto heterociclico sustituido con halogeno.
MY159870A (en) Piperazine compound capable of inhibiting prostaglandin d synthase
IN2012DN00770A (uk)
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
CY1117026T1 (el) Ετεροκυκλικες ενωσεις για αντιμετωπιση ή προληψη διαταραχων που προκαλουνται απο μειωμενη νευροδιαβιβαση σεροτονινης, νορεπινεφρινης ή ντοπαμινης